Affimed N.V. (AFMD)
How AFMD actually reacts to news — the realized, point-in-time move the market made, measured across 82 labeled events over the last three years with zero look-ahead.
AFMD’s median reaction, across the day.
Half of all Affimed N.V. news events land between -5.08% and +0.37% at 30 minutes.
Reaction stats as of 2026-08-18. Reaction = percent move vs. the price at the news timestamp.
Email me when AFMD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AFMD’s baseline. Nothing else.
Get “How AFMD reacts to news” as a PDF.
A free one-page summary: AFMD’s median reaction to news and the full breakdown by event type — the numbers on this page, in one page.
Recent AFMD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Affimed Announces Receipt of Nasdaq Delisting Notice | Press release | GlobeNewswire | -3.81% | +15.25% | |
| Form 6-K Affimed N.V. For: May 14 | SEC filing · Form 6-K | SEC EDGAR | -3.81% | +15.25% | |
| Affimed Announces Filing for the Opening of Insolvency Proceedings | Press release | GlobeNewswire | -14.74% | -17.03% | |
| Form 6-K Affimed N.V. For: May 13 | SEC filing · Form 6-K | SEC EDGAR | -14.74% | -17.03% | |
| Form NT 20-F Affimed N.V. For: May 01 | SEC filing · Form NT | SEC EDGAR | -2.33% | -12.73% | |
| Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting | Press release | GlobeNewswire | +2.56% | +2.48% | |
| Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting | Press release | GlobeNewswire | +0.72% | +2.09% | |
| Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement | Press release | GlobeNewswire | +0.00% | -2.25% | |
| Form 6-K Affimed N.V. For: Apr 21 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -2.25% | |
| Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting | Press release | GlobeNewswire | -0.30% | -6.88% | |
| Affimed to Present at the Leerink Partners Global Healthcare Conference 2025 | Press release | GlobeNewswire | -0.97% | -4.09% | |
| Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC) | Press release | GlobeNewswire | +0.57% | -13.71% | |
| Form 6-K Affimed N.V. For: Dec 17 | SEC filing · Form 6-K | SEC EDGAR | +0.57% | -13.71% | |
| Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | Press release | GlobeNewswire | -1.25% | -0.83% | |
| Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer | Press release | GlobeNewswire | +0.40% | -4.40% | |
| Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients | Press release | GlobeNewswire | +0.40% | -4.40% | |
| Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA) | Press release | GlobeNewswire | -2.88% | -4.53% | |
| Affimed Reports Third Quarter 2024 Financial Results & Business Update | Press release | GlobeNewswire | +2.39% | -2.93% | |
| Form 6-K Affimed N.V. For: Nov 14 | SEC filing · Form 6-K | SEC EDGAR | +2.39% | -2.93% | |
| Form EFFECT Affimed N.V. | SEC filing · Form EFFECT | SEC EDGAR | +0.13% | -2.34% | |
| Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024 | Press release | GlobeNewswire | +0.00% | -4.80% | |
| Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma | Press release | GlobeNewswire | +0.00% | +12.96% | |
| Form F-3 Affimed N.V. | SEC filing · Form F-3 | SEC EDGAR | -1.08% | -1.21% | |
| Form 6-K Affimed N.V. For: Oct 15 | SEC filing · Form 6-K | SEC EDGAR | -0.65% | +1.13% | |
| Form 6-K Affimed N.V. For: Sep 11 | SEC filing · Form 6-K | SEC EDGAR | -1.55% | -0.77% | |
| Affimed to Present at the Cantor Global Healthcare Conference 2024 | Press release | GlobeNewswire | -0.76% | -1.52% | |
| Affimed Reports Second Quarter 2024 Financial Results & Business Update | Press release | GlobeNewswire | -4.07% | -3.56% | |
| Form 6-K Affimed N.V. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -4.07% | -3.56% | |
| Affimed Appoints Shawn M. Leland as Chief Executive Officer | Press release | GlobeNewswire | -3.28% | -7.49% | |
| Form 6-K Affimed N.V. For: Sep 03 | SEC filing · Form 6-K | SEC EDGAR | -3.28% | -7.49% | |
| Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024 | Press release | GlobeNewswire | +0.00% | +6.25% | |
| Form 6-K Affimed N.V. For: Jun 26 | SEC filing · Form 6-K | SEC EDGAR | -1.42% | -3.02% | |
| Affimed Reports First Quarter 2024 Financial Results & Business Update | Press release | GlobeNewswire | +0.54% | -1.72% | |
| Form 6-K Affimed N.V. For: Jun 12 | SEC filing · Form 6-K | SEC EDGAR | +0.54% | -1.72% | |
| Form 6-K/A Affimed N.V. For: Jun 06 | SEC filing · Form 6-K | SEC EDGAR | -0.96% | -1.29% | |
| Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024 | Press release | GlobeNewswire | -1.00% | -5.31% | |
| Form 6-K Affimed N.V. For: Jun 03 | SEC filing · Form 6-K | SEC EDGAR | +4.63% | +54.32% | |
| Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort | Press release | GlobeNewswire | +4.63% | +54.32% | |
| Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer | Press release | GlobeNewswire | -0.73% | -2.66% | |
| Affimed Announces Annual General Meeting of Shareholders | Press release | GlobeNewswire | +0.71% | -3.78% | |
| Form 6-K Affimed N.V. For: May 28 | SEC filing · Form 6-K | SEC EDGAR | +0.71% | -3.78% | |
| Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024 | Press release | GlobeNewswire | -1.09% | -11.04% | |
| Form 6-K Affimed N.V. For: May 23 | SEC filing · Form 6-K | SEC EDGAR | -1.09% | -11.04% | |
| Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress | Press release | GlobeNewswire | +0.00% | +2.75% | |
| Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology | Press release | GlobeNewswire | +0.00% | -8.96% | |
| Affimed Reports 2023 Financial Results and Operational Progress | Press release | GlobeNewswire | -2.72% | -0.56% | |
| Form 20-F Affimed N.V. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.41% | -0.90% | |
| Form 6-K Affimed N.V. For: Mar 28 | SEC filing · Form 6-K | SEC EDGAR | -0.74% | +18.03% | |
| Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024 | Press release | GlobeNewswire | +1.70% | -4.73% | |
| Form 6-K Affimed N.V. For: Mar 11 | SEC filing · Form 6-K | SEC EDGAR | +6.69% | -1.67% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AFMD section they belong to.
More of the dataset.
AFMD earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Affimed N.V.'s median reaction calculated?
Every labeled AFMD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 82 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 28% of AFMD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-18.
Does AFMD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.